A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors. (4th November 2015) - Hecht, J Randolph; Raman, Steven; Sze, Daniel Y; Lockhart, A Craig; Moss, Rebecca A; Liu, Kate; Chou, Jeffrey; Reid, Tony